Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug971 | Chiropractic care (one visit) Wiki | 0.33 |
| drug1486 | Emotion- and Relationship-Focused Therapeutic Interview Wiki | 0.33 |
| drug4737 | Web-based self-report questionnaires Wiki | 0.33 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug970 | Chiropractic care (more than one visit) Wiki | 0.33 |
| drug1695 | Focus Group Interviews Wiki | 0.33 |
| drug1562 | Exercise Testing and Training Wiki | 0.33 |
| drug985 | Choices and judgements Wiki | 0.33 |
| drug4306 | Tele-yoga therapy Wiki | 0.33 |
| drug1856 | Health and work environment information and processes Wiki | 0.33 |
| drug3381 | Primary care Wiki | 0.33 |
| drug2187 | Interview Wiki | 0.15 |
Navigate: Correlations HPO
There are 9 clinical trials
The wars in Iraq and Afghanistan are creating a new generation of Veterans, including an increasing number of women Veterans, who present with comorbid PTSD and chronic pain conditions from recent deployment-related physical injuries and exposure to psychological trauma. Health behavior change has become increasingly important in treating these conditions and proactively preventing long-term negative health sequelae, in order to benefit these Veterans directly and reduce the growing challenges to our healthcare system. The proposed CDA-2 program of research will use an innovative translational research approach to study whether a chronic progressive -based exercise program will reduce chronic pain in patients with PTSD and to elucidate and modify potential PTSD-related deficiencies in neurobiological and psychological responses to exercise to optimize the physical and psychological benefits of exercise for these individuals.
Description: To be administered at: Screening Evaluation & Endpoint 13 week exercise test sessions This 30-item structured interview is designed to assess both the 17 symptoms of PTSD and the 8 hypothesized associated features. The scale yields a dichotomous diagnosis of PTSD, and also provides a continuous score of frequency and severity for each symptom. In addition, a behaviorally anchored probe question is provided for each symptom to increase the reliability of administration. The CAPS-5 is currently in the process of being validated however its previous version demonstrated excellent sensitivity (.81) and specificity (.95).57
Measure: Change from Baseline: Clinician Administered PTSD Scale -5 Time: Baseline and endpoint (at 13 weeks)Description: The WHY-MPI has been demonstrated to be applicable across a variety of clinical pain conditions. Its brevity, validity/ reliability, self-report nature and ease of scoring make it ideal for both clinical and research purposes. The WHY-MPI is sensitive to change following rehabilitation. Please note only the interference subscale of the WHY-MPI will be administered in this study.
Measure: Change from Baseline: West Haven=Yale Multidimensional Pain Inventory- Interference Subscale (WHY-MPI) Time: Baseline, Midpoint (at 6 weeks) and Endpoint (at 13 weeks)HealthAtWork - a measure for increased coping and work participation -An effect analysis of a health- and work environment intervention at the workplace. Part 1:quantitative data collection The main objective of this study is to investigate the effect of the workplace intervention in the new Norwegian national concept HealthAtWork (HelseIArbeid) through a pragmatic cluster-randomized study. The main hypothesis is that this interdisciplinary health and welfare intervention at the workplace reduces sick leave and improves mastering of common health problems more efficiently than a conventional welfare intervention. More specifically, it is hypothesized that the HealthAtWork intervention has a better cost-effectiveness in terms of sick leave, use of health services and coping with common health problems indicated by an increased health-related quality of life.
Description: Sickness absence data from workplace-registers; Difference-in-difference analyses of sickness absence within and between intervention and control group (% of planned workdays).
Measure: Change in overall sickness absence rates (self- and physician-certified) at the workplace (unit level) Time: Time period 24 months prior to randomization compared to the time period 12-24 months after randomizationDescription: Difference-in-difference analyses of health service refunds from National register of control and health service refunds (KUHR database, Helsedirektoratet) and Norwegian Patient Register (NPR, Helsedirektoratet) within and between intervention and control group.
Measure: Change in healthcare utilization Time: Time period 24 months prior to randomization compared to the time period 12-24 months after randomizationDescription: Difference-in-difference analyses of HRQoL within and between intervention and control groups by use of EQ-5D/EQ-VAS.The EuroQol descriptive system EQ-5D-5L describes health along five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Participants rate each dimension along five severity levels from no problems (1) to extreme problems (5).The resulting combination (5 to the power of 5 = 3,125 possible combinations) is attached a utility value based on a national value set on a scale from 1(best health) to a 0(or even lower) for worst health.A Norwegian value set is currently being developed.The EQ-VAS (EuroQol vertical visual analogue scale;0 as worst,100 as best possible score) is an integral part that has to be included when using the EQ-5D questionnaire.It offers important, complementary information on respondents' valuations of their HRQoL that are not necessarily captured by use of the 5 dimensional descriptive part of this instrument.
Measure: Change in health-related quality of life (HRQoL) by EQ-5D-5L utility value, including EQ-VAS score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Cost-effectiveness analysis based on primary outcome 3 and cost-benefit analyses based on primary outcome 1 and 2. Comparing the intervention arms in terms of incremental costs based on direct- and indirect costs related to interventions throughout the intervention period.
Measure: Health-economic analyses Time: Time period 24 months prior to randomization through 24 months after randomizationDescription: Data from the Norwegian national register of sickness absence (NAV sykefraværsregister); Difference-in-difference analyses of individual sickness absence rates within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in physician-certified sickness absence rates (individual level) Time: Time period 24 months prior to randomization compared to the time period 12-24 months after randomizationDescription: Data from the questionnaires; Difference-in-difference analyses of self-certified sickness absence rates within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in self-certified sickness absence rates (individual level) Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Demand-Control-Support-Questionnaire, short Swedish version (Theorell et al 1991), 11 items on demand and control, and 6 items on support, each with scores 1-4, subscales for demand, control and support. Low scores indicate low demand, control and support. Difference-in-difference analyses of psychosocial work environment within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in psychosocial work environment by Demand-Control-Support-Questionnaire score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Nondirective and Directive support Survey (NDSS-16). 16 items scored 1-5. Subscales for directive support (8 items, scale 8-40) and non-directive support (8 items, scale 8-40), the higher the score the more support. Difference-in-difference analyses of social support from colleagues within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in social support from colleagues by NDSS-16 score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Global Job Satisfaction (GJS). Quinn and Shepard, 1974, 5 items scores 1-5 and 1-3, highest number indicate best job satisfaction. Difference-in-difference analyses of job satisfaction within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in job satisfaction by GJS score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Subjective Health Complaints (SHC), Eriksen et al. 1999, 29 items scored with 4 levels from 0 (no complaints) to 3 (serious complaints), total score and subscale for mental complaints and musculoskeletal pain. Difference-in-difference analyses of subjective health complaints within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in subjective health complaints by SHC score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationDescription: Change in score of the Whitheley index. The Whiteley-7 index (WI-7) includes questions regarding health anxiety covering different dimensions such as self-experienced health concern, frequency and severity of health concerns, influence of media on subjective health concerns and experiencing of health symptoms. Each response is graded on a 1-5 Likert Scale, where "1=not at all" to "5=very much", enabling to calculate a product score of maximum 35, a higher value indicating higher level of health anxiety. The 7th question in the Norwegian version of WI-7 is not validated for use in a general Norwegian population and is therefore not included in the use of total score sum. It can, however, be used for repeated analyses, both within study time and for comparison with data from the Tromsø study 7. Difference-in-difference analyses of health anxiety within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in health anxiety by Whitheley index score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomization; comparison with Tromsø Study 7Description: Satisfaction of life scale (SWLS). Five items where each has response options ranged from 1 (strongly disagree) to 7 (strongly agree), sum score is calculated. The higher the sum score, the higher is the satisfaction of life. Change in sum score of the first 3 items (the last two are sensitive to age). Difference-in-difference analyses of subjective health complaints within and between intervention and control group. Possible impact of Covid-19 pandemic will be addressed.
Measure: Change in Satisfaction of life by SWLS score Time: Enrollment (Q1) to 12 months (Q2) and 24 months (Q3) after randomizationPersons with COPD have both chronic musculoskeletal pain and dyspnea that require accurate diagnosis and treatment, ultimately to optimize functional status. The investigators propose to use advanced neuroimaging techniques to understand central mechanisms of chronic pain, dyspnea, and physical activity promotion in COPD. The investigators' novel proposal to correlate subjective symptoms (chronic pain and dyspnea) with an objective central biomarker (resting state functional connectivity) and examine their changes in response to a non-pharmacological, non-addictive physical activity intervention will personalize the care of Veterans with COPD.
Description: Cortical thickness will be measured by brain MRIs that will assess functional connectivity and structural variables. Cortical thickness will be reported in millimeters.
Measure: Cortical thickness Time: 3 monthsDescription: Pain intensity will be measured with the Brief Pain Index.
Measure: Pain Intensity Time: 3 monthsDescription: Dyspnea will be measured with the modified Medical Research Council scale
Measure: Dyspnea Time: 3 monthsThe study aims to evaluate the working environments of individuals working from home during the covid-19 outbreak and the effect of the working environments on their musculoskeletal system. The study will include 500 people between the ages of 18-65 who works from home (works in the office before isolation) as a part of Covid-19 isolation measure. The working environment of the individuals participating in the study will be evaluated with The Rapid Office Strain Assessment (ROSA). Musculoskeletal symptoms will be analysed by using the Standardised Nordic Questionnaries (NMQ). Pain will be analysed by using Visual Analogue Scale (VAS)
Description: The working environment of the individuals participating in the study will be evaluated with The Rapid Office Strain Assessment (ROSA).
Measure: The Rapid Office Strain Assessment (ROSA) Time: 30 minutesDescription: The NMQ can be used as a questionnaire or as a structured interview
Measure: The Standardised Nordic Questionnaries (NMQ) Time: 15 minutesDescription: Pain will be analysed by using Visual Analogue Scale (VAS)
Measure: Visual Analog Scale (VAS) Time: 2 minutesIn 2017, Socialstyrelsen reported that mental ill-health in young adults had increased by almost 70% in the previous10 years. A 2014 report showed that 5% of men and 11% of women 18-24 years were diagnosed with depression or anxiety in Stockholm County. Furthermore, 41% of women 21-24 years have self reported psychological distress. Regarding pain, 28% of men and 36% of women 16-24 years have disabling neck pain. Little is known about the etiology and prognosis of poor mental health in university students. The aim is to advance knowledge about the etiology of depression, anxiety, stress and pain in undergraduate university students. The investigators will study a cohort of students at full-year programs at universities in the Stockholm area. Primary research questions are whether modifiable factors such as sleep quality, lifestyle, screen time and work environment are independent risk factors for incident episodes or unfavorable trajectories of depression, anxiety and pain in men and women? To be able to answer these research questions we designed a prospective cohort study targeting 5000 university students.
Description: Repeated measures with web-based questionnaires, 5 times (every 3 months), over one year. Outcome measures: Musculoskeletal pain will be measured with the The Nordic Musculoskeletal Questionnaire (NMQ). The NMQ measure musculoskeletal symptoms, and pain intensity in nine body areas: neck, shoulder, elbow, wrists/hands, upper back, lower back, hips/thighs/buttocks, knees, ankle/feet. The questions were modified to assess previous month rather than the previous 12 months as per the original NMQ. No symptoms = a pain score of 0, while the participants who report musculoskeletal symptoms also report average pain intensity over the last month, on a scale from 0 (no complaints), to 9 (pain 'worst possible'). Weekly text messages measure levels of pain.
Measure: Pain Time: 2019-2022Description: Repeated measures with web-based questionnaires, 5 times (every 3 months), over one year. Outcome measures: Depression Anxiety Stress Scale-21(DASS-21). DASS-21 includes three subscales (range 0-3, score 0-63, higher scores = more symptoms) to measure depression, anxiety and stress symptoms in nonclinical populations. Weekly text messages measure levels anxiety and depression.
Measure: Mental health problems Time: 2019-2022Description: Web-based questionnaires comparing students entering the study before the Covid-19 pandemic and after. Outcome measures: Musculoskeletal pain will be measured with the The Nordic Musculoskeletal Questionnaire (NMQ). The NMQ measure musculoskeletal symptoms, and pain intensity in nine body areas: neck, shoulder, elbow, wrists/hands, upper back, lower back, hips/thighs/buttocks, knees, ankle/feet. The questions were modified to assess previous month rather than the previous 12 months as per the original NMQ. No symptoms = a pain score of 0, while the participants who report musculoskeletal symptoms also report average pain intensity over the last month, on a scale from 0 (no complaints), to 9 (pain 'worst possible'). Weekly text messages measure levels of pain.
Measure: Pain related to the Covid-19 pandemic. Time: 2019-2020Description: Web-based questionnaires comparing students entering the study before the Covid-19 pandemic and after. Outcome measures: Depression Anxiety Stress Scale-21(DASS-21). DASS-21 (3 subscales, range 0-3, score 0-63, higher scores = more symptoms) to measure depression, anxiety and stress symptoms in nonclinical populations. Weekly text messages measure levels of anxiety and depression.
Measure: Mental health problems related to the Covid-19 pandemic. Time: 2019-2020Covid-19 outbreak and lockdown measures raised significant concerns over clinical management of chronic pain patients around the world. Patients with chronic musculoskeletal pain (CMSP) are at high risk of physical disability, psychological distress, and poor quality of life. Analgesic medications were main management during lockdown, but opioid-related concerns have prompted to find immediate alternatives. Present study was undertaken to determine whether patients randomized to tele-yoga therapy would experience less pain, disability and improved global health, adherence and satisfaction, compared with patients assigned to usual care.
Description: Pain was assessed using the Brief Pain Inventory (BPI), which rates the severity of pain on 4 items (current, worst, least, and average pain in past week)
Measure: Severity of pain Time: From baseline to 6-week post interventionDescription: Interference of pain in 7 areas (mood, physical activity, work, social activity, relations with others, sleep, enjoyment of life) were reported using BPI
Measure: Interference of pain Time: From baseline to 6-week post interventionDescription: 7-point global rating of pain change was used to assess change in pain
Measure: Global rating of change in pain Time: From baseline to 6-week post interventionaDescription: 10 point scale was used to assess intervention-specific satisfaction
Measure: Intervention specific satisfaction Time: From baseline to 6-week post interventionaThe goal of the study is to determine whether a brief, therapeutic interview can help patients improve their pain and health by addressing psychological issues that are known to drive chronic musculoskeletal pain. This randomized, controlled trial tests the efficacy of a brief, one-session therapeutic interview for patients with chronic musculoskeletal pain and histories of childhood adversity. Adults with chronic musculoskeletal pain will be randomized to either a therapeutic interview condition or a waitlist control condition. The therapeutic interview will be 90-minute session during which participants will be encouraged to disclose stressful experiences, express important emotions, and identify connections between their life stress and their pain, which we hope will increase their psychological attributions for pain and reduce their pain, interpersonal problems, and psychological distress. The study will compare the therapeutic interview condition to a delayed interview condition and will follow patients for 5 weeks to identify changes in response to the interview. Participants in the therapeutic interview condition are expected to show more improvement on pain severity, pain interference, psychological distress, interpersonal function, and psychological attitudes toward pain at follow-up, relative to participants in the delayed interview condition.
Description: Brief Pain Inventory pain severity scale (0 - 10; higher values = greater pain severity)
Measure: Change in pain severity from baseline to 5-week follow-up Time: 5-week follow-upDescription: Brief Pain Inventory pain interference scale (0 - 10; higher values = greater pain interference)
Measure: Change in pain interference from baseline to 5-week follow-up Time: 5-week follow-upDescription: PROMIS anxiety scale (0 to 4; higher values = greater anxiety)
Measure: Change in anxiety from baseline to 5-week follow-up Time: 5-week follow-upDescription: PROMIS depression scale (0 to 4; higher values = greater depression)
Measure: Change in depression from baseline to 5-week follow-up Time: 5-week follow-upDescription: PROMIS anger scale (0 to 4; higher values = greater anger)
Measure: Change in anger from baseline to 5-week follow-up Time: 5-week follow-upDescription: Rathus Assertiveness Schedule short form (- 3 to + 3; higher values = greater assertion)
Measure: Change in assertiveness from baseline to 5-week follow-up Time: 5-week follow-upDescription: Affect Phobia Test (1 to 5; lower values = affect phobia)
Measure: Change in affect phobia from baseline to 5-week follow-up Time: 5-week follow-upDescription: Pain attributions psychological subscale (0 to 4; higher values = greater psychological attribution)
Measure: Change in pain attributions to psychological processes from baseline to 5-week follow-up Time: 5-week follow-upDescription: Pain attributions brain subscale (0 to 4; higher values = greater brain attributions)
Measure: Change in pain attributions to brain processes from baseline to 5-week follow-up Time: 5-week follow-upDescription: Alcohol use item (1 to 7; higher = greater alcohol use)
Measure: Change in alcohol use frequency from baseline to 5-week follow-up Time: 5-week follow-upDescription: Item assessing pain medication use (1 to 5; higher = greater medication use)
Measure: Change in pain medication use from baseline to 5-week follow-up Time: 5-week follow-upThis is a pragmatic controlled clinical trial taking place in the first phase of COVID-19 lockdown re-opening in Spain. Patients of 52 chiropractic clinics were invited to participate in a pseudo-random order (one out of every three contacted patients) as they were contacted to either schedule an appointment with their current chiropractor or not, depending on the clinic's and the patient's availability. Patients would receive chiropractic in-person care (one or more than one visits) or no care at all, for a two-week period. According to the care received, they were assigned to one of three groups (receiving no care, receiving care once, and more than once). Participants filled an online questionnaire with self-reported outcome-measures at the beginning of the two week period. A follow-up questionnaire was completed 14 days after.
Description: Numerical rating scale (0-10, 0 meaning no pain, 10 meaning worst pain imaginable)
Measure: Pain intensity Time: 14 daysDescription: Likert Scale from better (1) to worst (4) outcomes, 1: occasionally, 4: constantly
Measure: Pain frequency Time: 14 daysDescription: Likert Scale of self-perceived improvement, from better (1) to worst (5) outcomes, 1: much better, 5: much worse
Measure: Pain evolution Time: 14 daysDescription: Validated subscale form the Brief Pain Inventory, 6 categories from 0 to 10 each, the lower, the better outcomes, out of a minimal of 0 and total of 60.
Measure: Pain interference Time: 14 daysDescription: Validated questionnaire. Short version 4 items, Likert scale from 0 to 4, lowest score (0) better outcomes, highest score (16) worst outcomes
Measure: Pain Catastrophizing Scale Time: 14 daysDescription: Validated questionnaire. Short version 11 items, Likert scale from 1 to 4, lowest score (11) better outcomes, highest score (44) worst outcomes
Measure: Tampa Scale Kinesiophobia Time: 14 daysDescription: Validated questionnaire 7 items, Likert scale from 0 to 3, lowest score (0) better outcomes, highest score (21) worst outcomes
Measure: General Anxiety Disorder scale Time: 14 daysDescription: Validated questionnaire. Short version 12 items, Likert scale from 1 to 5, lowest score (12) better outcomes, highest score (60) worst outcomes
Measure: Intolerance of Uncertainty Scale Time: 14 daysDescription: Validated questionnaire 10 items, Likert scale from 1 to 10, lowest score (10) WORST outcomes, highest score (100) BETTER outcomes
Measure: General Self-Efficacy scale Time: 14 daysDescription: Questionnaire, subscale 10 items, Likert scale from 1 to 4, lowest score (1) WORST outcomes, highest score (40) BETTER outcomes
Measure: Fear of Illness and Virus Evaluation Time: 14 daysWorldwide, the COVID-19 pandemic continues to grow. Although COVID-19 mainly affects the lungs and internal organs, musculoskeletal injury from this disease was reported with the presentation of marked elevation in creatine kinase and lactate dehydrogenase levels. Patients with post-acute COVID-19 are considered patients with a post-intensive syndrome (PICS) that results in loss of functional independence. In the physical and rehabilitation medical field, various modalities with therapeutic exercise can be used to manage pain by a physical therapist and psychiatrist. Pain management is particularly important during the COVID-19 pandemic because of the reduced accessibility to hospitals and medical resources.
Description: the characterization of the pain. Total of 24. > 11 neuropathic pain.
Measure: Self-reported Version of the Leeds Assessment of Neuropathic Symptoms and Signs Time: BaselineDescription: the characterization of the pain
Measure: PainDETEC Time: BaselineDescription: To measure quality of life, grade ranging from 0 (the worst possible health status) to 100 (the best possible health status)
Measure: EuroQol-5D Time: BaselineDescription: To measure psychological status. 0-7 = Normal; 8-10 = Borderline abnormal (borderline case), 11-21 = Abnormal (case)
Measure: The Hospital Anxiety and Depression Scale Time: BaselineAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports